Purpose In The Pressure: Catherine Dargan On Building Billion-Dollar Deals [Forbes]
Avidity Biosciences, Inc. (RNA)
Company Research
Source: Forbes
s global chair of Covington's Corporate Practice and head of the M&A team, Catherine Dargan has overseen work that spans multibillion-dollar mergers, cross-border acquisitions and complex carve-outs for some of the world's largest and most sophisticated companies. Dargan began her career at the firm's DC headquarters, where Covington's deep regulatory bench provided a natural edge for a life-sciences niche. She steadily built a portfolio that evolved into one of the premier M&A practices, with clients like Merck, Bristol Myers, AbbVie, Gilead and Novartis. Over 25 years of practice, Dargan expanded her cross-industry expertise, carving a spot in the upper echelons of an elite field by leading blockbuster deals, including Novartis' recent $12 billion acquisition of Avidity Biosciences, Inc. She works with clients in a wide range of business categories—from technology to manufacturing to gaming. And she has grown her considerable book of business by being nimble, knowledgeable and in
Show less
Read more
Impact Snapshot
Event Time:
RNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNA alerts
High impacting Avidity Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
RNA
News
- Avidity Biosciences, Inc. (RNA): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-WTRG, RNA, FIZN, and TCBXPR Newswire
- Novartis sees sales boost from key cancer drugs [Yahoo! Finance Canada]Yahoo! Finance Canada
- Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs [CNBC]CNBC
- Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44PR Newswire
RNA
Earnings
- 11/10/25 - Miss
RNA
Sec Filings
- 12/5/25 - Form SCHEDULE
- 11/24/25 - Form PREM14A
- 11/20/25 - Form DEFA14A
- RNA's page on the SEC website